BeiGene fur­ther in­vests in AD­Cs with sol­id tu­mor part­ner Du­al­i­ty­Bio, a BioN­Tech col­lab­o­ra­tor

BeiGene is ex­pand­ing its can­cer ar­se­nal with an an­ti­body-drug con­ju­gate deal, en­list­ing the same Shang­hai biotech that teamed up with BioN­Tech in April.

The sol­id …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER